Not exact matches
Cirius Therapeutics, a clinical - stage pharmaceutical company, is
developing MSDC - 0602K, a next - generation insulin sensitizer for the treatment of
nonalcoholic steatohepatitis (NASH).
«However, only a smaller number of these individuals will
develop the most severe form of this disease known as
nonalcoholic steatohepatitis or NASH.»
Spurlock's binge placed him at risk for
developing a syndrome called
nonalcoholic steatohepatitis, or NASH.
Roughly one - quarter of Americans — an estimated 100 million adults and children — have NAFLD, which can progress to a more serious form called
nonalcoholic steatohepatitis, which in turn can
develop into cirrhosis, liver cancer and liver failure.